Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how

Dual antiplatelet therapy (DAPT) for 6–12 months, followed by lifelong aspirin monotherapy is considered an effective standard therapy for the prevention of thrombo-ischemic events in patients with acute and chronic coronary syndrome (ACS, CCS) undergoing percutaneous coronary intervention (PCI) or...

Full description

Bibliographic Details
Main Authors: Marie Muthspiel, Christoph C. Kaufmann, Achim Leo Burger, Benjamin Panzer, Freek W. A. Verheugt, Kurt Huber
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
percutaneous coronary intervention (PCI)
short dual antiplatelet therapy (short DAPT)
de-escalation
P2Y12-inhibitor
bleeding
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1008194/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1008194/full

Similar Items